Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT05187182 |
| Title | CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer |
| Recruitment | Not yet recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Washington University School of Medicine |
| Indications |
gastroesophageal junction adenocarcinoma |
| Therapies |
CA-4948 + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin CA-4948 + Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab + Trastuzumab |
| Age Groups: | senior | adult |
| Covered Countries | USA |